Victory Capital Management Inc. Cuts Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Victory Capital Management Inc. trimmed its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 16.1% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 201,306 shares of the biopharmaceutical company’s stock after selling 38,718 shares during the quarter. Victory Capital Management Inc.’s holdings in Dynavax Technologies were worth $2,243,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares during the last quarter. US Bancorp DE boosted its holdings in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new position in Dynavax Technologies during the 3rd quarter worth approximately $45,000. Nisa Investment Advisors LLC increased its stake in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the period. Finally, Algert Global LLC purchased a new position in Dynavax Technologies in the 2nd quarter worth approximately $140,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 8th. The Goldman Sachs Group decreased their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.42 on Monday. The firm has a fifty day simple moving average of $11.50 and a two-hundred day simple moving average of $11.32. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.63 billion, a PE ratio of 95.55 and a beta of 1.34.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.